AbbVie Inc (ABBV)vsPhreesia Inc (PHR)
ABBV
AbbVie Inc
$264.34
-0.29%
HEALTHCARE · Cap: $454.36B
PHR
Phreesia Inc
$10.15
+1.50%
HEALTHCARE · Cap: $626.92M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 12580% more annual revenue ($64.39B vs $507.79M). ABBV leads profitability with a 9.8% profit margin vs 2.1%. PHR trades at a lower P/E of 56.1x. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
PHR
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.5%
Fair Value
$152.16
Current Price
$264.34
$112.18 premium
Margin of Safety
+71.9%
Fair Value
$44.43
Current Price
$10.15
$34.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Earnings expanding 200.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 2.8% — below average capital efficiency
2.1% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : PHR
The strongest argument for PHR centers on EPS Growth, Debt/Equity, Price/Book. Revenue growth of 10.4% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : PHR
The primary concerns for PHR are Market Cap, Return on Equity, Profit Margin. A P/E of 56.1x leaves little room for execution misses. Thin 2.1% margins leave little buffer for downturns.
Key Dynamics to Monitor
PHR carries more volatility with a beta of 0.86 — expect wider price swings.
PHR is growing revenue faster at 10.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (73/100 vs 52/100) and 10.2% revenue growth. PHR offers better value entry with a 71.9% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Phreesia Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Phreesia, Inc. provides integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company is headquartered in Raleigh, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?